- Home
- SB vs VERV Comparison
SB vs VERV Comparison
Compare SB & VERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- VERV
- Stock Information
- Founded
- SB 2007
- VERV 2018
- Country
- SB Monaco
- VERV United States
- Employees
- SB N/A
- VERV N/A
- Industry
- SB Marine Transportation
- VERV Medicinal Chemicals and Botanical Products
- Sector
- SB Consumer Discretionary
- VERV Health Care
- Exchange
- SB Nasdaq
- VERV Nasdaq
- Market Cap
- SB 395.3M
- VERV 384.2M
- IPO Year
- SB 2008
- VERV 2021
- Fundamental
- Price
- SB $3.77
- VERV $11.06
- Analyst Decision
- SB Strong Buy
- VERV Buy
- Analyst Count
- SB 1
- VERV 9
- Target Price
- SB $5.00
- VERV $14.75
- AVG Volume (30 Days)
- SB 403.1K
- VERV 7.8M
- Earning Date
- SB 07-28-2025
- VERV 08-07-2025
- Dividend Yield
- SB 5.35%
- VERV N/A
- EPS Growth
- SB N/A
- VERV N/A
- EPS
- SB 0.67
- VERV N/A
- Revenue
- SB $290,312,000.00
- VERV $59,613,000.00
- Revenue This Year
- SB N/A
- VERV $27.75
- Revenue Next Year
- SB $13.41
- VERV N/A
- P/E Ratio
- SB $5.57
- VERV N/A
- Revenue Growth
- SB N/A
- VERV 271.44
- 52 Week Low
- SB $3.02
- VERV $2.87
- 52 Week High
- SB $6.22
- VERV $11.41
- Technical
- Relative Strength Index (RSI)
- SB 58.59
- VERV 84.74
- Support Level
- SB $3.81
- VERV $5.88
- Resistance Level
- SB $3.91
- VERV $11.41
- Average True Range (ATR)
- SB 0.08
- VERV 0.49
- MACD
- SB -0.01
- VERV 0.64
- Stochastic Oscillator
- SB 65.79
- VERV 95.00
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About VERV Verve Therapeutics Inc.
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.